LONDON, 29 October 2021: Arix Bioscience plc (LSE: ARIX, “Arix”), a global venture capital company focused on investing in and building breakthrough biotech companies, today notes that its portfolio company, Aura Biosciences, Inc., (“Aura”), has announced the pricing of its initial public offering of 5,400,000 shares of common stock at a public offering price of […]